Cross-species differential plasma protein binding of MBX-102/JNJ39659100: A novel PPAR-γ agonist

PPAR Research

Volumn , Issue , 2008, Pages

  Clarke, Holly J ^a,b   Gregoire, Francine ^a   Ma, Fang ^a   Martin, Robert ^a   Zhao, Spring ^a   Lavan, Brian E ^a  

^a Metabolex Inc   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METAGLIDASEN; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; EQUILIBRIUM DIALYSIS; HUMAN; HUMAN CELL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA PROTEIN BINDING; PROTEIN DOMAIN; RAT;

EID: 53149121998     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/465715     Document Type: Article

References (21)

1. Aronow W. S., Harding P. R., Khursheed M., Vangrow J. S., Papageorge's N. P., Effect of halofenate on serum uric acid Clinical Pharmacology & Therapeutics 1973 14 3 371 373
2. Aronow W. S., Harding P. R., Khursheed M., Vangrow J. S., Papageorge's N. P., Mays J., Effect of halofenate on serum lipids Clinical Pharmacology & Therapeutics 1973 14 3 358 365
3. Aronow W. S., Vangrow J., Pagano J., Khemka M., Vawter M., Papageorge's N. P., Long-term effect of halofenate on serum lipids Current Therapeutic Research: Clinical and Experimental 1974 16 9 897 903
4. Aronow W. S., Vangrow J. S., Nelson W. H., Halofenate: an effective hypolipemia- and hypouricemia-inducing drug Current Therapeutic Research: Clinical and Experimental 1973 15 12 902 906
5. Aronow W. S., Vicario M. D., Moorthy K., King J., Vawter M., Papageorge's N. P., Long-term efficacy of halofenate on serum triglyceride levels Current Therapeutic Research: Clinical and Experimental 1975 18 6 855 861
6. Dujovne C. A., Azarnoff D. L., Pentikainen P., Manion C., Hurwitz A., Hassanein K., A two-year crossover therapeutic trial with halofenate and clofibrate The American Journal of the Medical Sciences 1976 272 3 277 284
7. Feldman E. B., Gluck F. B., Carter A. C., Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia The Journal of Clinical Pharmacology 1978 18 5-6 241 248
8. Krut L. H., Seftel H. C., Joffe B. I., Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia South African Medical Journal 1977 51 11 348 352
9. Jain A. K., Ryan J. R., McMahon F. G., Potentiation of hypoglycemic effect of sulfonylureas by halofenate The New England Journal of Medicine 1975 293 25 1283 1286
10. Kohl E. A., Magner J. A., Persellin S. T., Vaughan G. M., Kudzma D. J., Friedberg S. J., Improved control of non-insulin-dependent diabetes mellitus by combined halofenate and chlorpropamide therapy Diabetes Care 1984 7 1 19 24
11. Kudzma D. J., Friedberg S. J., Potentiation of hypoglycemic effect of chlorpropamide and phenformin by halofenate Diabetes 1977 26 4 291 295
12. Allen T., Zhang F., Moodie S. A., Halofenate is a selective peroxisome proliferator-activated receptor γ modulator with antidiabetic activity Diabetes 2006 55 9 2523 2533
13. Zhang F., Lavan B. E., Gregoire F. M., Selective modulators of PPAR- γ activity: molecular aspects related to obesity and side-effects PPAR Research 2007 2007 7
14. Krieter P. A., Colletti A. E., Doss G. A., Miller R. R., Disposition and metabolism of the hypoglycemic agent pioglitazone in rats Drug Metabolism and Disposition 1994 22 4 625 630
15. Lin Z. J., Desai-Krieger D., Shum L., Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry Journal of Chromatography B 2004 801 2 265 272
16. Yi P., Hadden C. E., Annes W. F., The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor α-γ dual, γ -dominant agonist in mice, rats, and monkeys Drug Metabolism and Disposition 2007 35 1 51 61
17. Greenspan M. D., Germershausen J. I., Mackow R., Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes Biochimica et Biophysica Acta 1975 380 2 190 198
18. Wosilait W. D., Nagy P., The distribution of halofenate in plasma: a comparative analysis using Scatchard vs. stepwise association constants Research Communications in Chemical Pathology and Pharmacology 1976 14 1 75 81
19. Rich R. L., Day Y. S. N., Morton T. A., Myszka D. G., High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE Analytical Biochemistry 2001 296 2 197 207
20. Day Y. S. N., Myszka D. G., Characterizing a drug's primary binding site on albumin Journal of Pharmaceutical Sciences 2003 92 2 333 343
21. Collins J. M., Klecker R. W. Jr., Evaluation of highly bound drugs: interspecies, intersubject, and related comparisons The Journal of Clinical Pharmacology 2002 42 9 971 975